HIV/AIDS Topics HIV Disease Progression Life Expectancy & Survival
People with Well-Controlled HIV Can Match Lifespan of HIV Negatives
- Details
- Category: HIV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
People with HIV who are able to achieve good viral suppression and CD4 cell recovery on antiretroviral therapy (ART) have a mortality rate similar to that of uninfected people in the general population, according to results from the large SMART and ESPRIT studies, published in the March 27, 2013 issue of AIDS.
Liver Toxicity Uncommon with Modern Antiretroviral Drugs, but Higher Risk for HIV/HCV Coinfected
- Details
- Category: HIV Treatment
- Published on Wednesday, 05 December 2012 00:00
- Written by Liz Highleyman
Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however, and early hepatitis C treatment may improve the tolerability of HIV therapy.
HIV11: Life Expectancy in Older People with HIV Could Exceed the Average - As Long As ART Keeps Working
- Details
- Category: HIV Treatment
- Published on Tuesday, 20 November 2012 00:00
- Written by Gus Cairns
The latest forecasts of life expectancy in people with HIV in the U.K., based on mortality data from the UK Collaborative HIV Cohort (UK CHIC) study, show that the average life expectancy of people on antiretroviral therapy (ART) with a CD4 count over 350 cells/mm3 is now very close to the national average, the 11th International Congress on Drug Therapy in HIV Infection in Glasgow heard last week. 
HIV11: New Studies Challenge Evidence of Reduced Abacavir Potency When Viral Load Is High
- Details
- Category: HIV Treatment
- Published on Friday, 30 November 2012 00:00
- Written by Gus Cairns
An analysis of 2 studies of the new HIV integrase inhibitor dolutegravir presented at the 11th International Congress on Drug Therapy in HIV Infection this month in Glasgow had the incidental effect of bringing into question evidence from a previous study suggesting that the nucleoside reverse transcriptase inhibitor abacavir (Ziagen, also in the Epzicom or Kivexa coformulation) was less potent in people starting HIV therapy with high viral loads than another NRTI drug, tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations). 
Web Design and Development by